id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-329542-srls2syv	Ma, Alice	Stroke and Thromboprophylaxis in the era of COVID-19	2020-10-09		.txt	text/plain	2443	131	37	In the rapidly evolving COVID-19 pandemic, many patients presenting with acute ischemic stroke may be potentially infected with the Severe Acute Respiratory Syndrome Coronavirus (SARS CoV-2) agent. In the critically ill, the PREVENT trial demonstrated no reduction in the incidence of proximal DVT from adjunctive use of IPC in patients already prescribed drug prophylaxis with unfractionated heparin or low molecular weight heparin [27] . The choice of drug will largely depend on local guidelines or institutional preference, however altered pharmacokinetics in the critically ill should be considered in addition to the potential prothrombotic state generated by COVIDof fibrinogen and d-dimer, and introduced higher intensity thromboprophylaxis regimes and therapeutic anticoagulation in selected patients ( Anticoagulation considerations in COVID-19 patients who develop stroke A situation that warrants consideration is that of patients hospitalized because of COVID-19 infection who have had VTE prophylaxis initiated on admission, and subsequently developed a large vessel ischemic stroke, an occurrence with a reported frequency up to 4.5% [23] .	./cache/cord-329542-srls2syv.txt	./txt/cord-329542-srls2syv.txt